DALKHIMPHARM has begun manufacturing Loxoprofen for the Russian market, a generic version of Loxonin (INN Loxoprofen), the most prescribed non-steroidal anti-inflammatory drug (NSAID) in Japan noted for its fast and gentle action combined with high efficiency.
Loxoprofen is a fast-acting analgesic that exhibits pronounced anti-inflammatory and antipyretic effects, with virtually no side effects.
The company reported it is actively working to introduce new medicines to the market and has already launched Diamidazepam (INN: hydrazinocarbonylmethylbromophenyldihydrobenzodiazepine), a unique anxiolytic (tranquilizer) in the benzodiazepine class designed for daily use in treating neurotic and neurosis-like conditions such as anxiety, fear, irritability, insomnia, and psychopathy, as well as diencephalic pathologies, including migraine, logoneurosis, and alcoholism as part of complex treatment.
«It is important to note that DALKHIMPHARM chemists synthesized a molecule of a substance that a pharmaceutical company in Ukraine stopped supplying to the Russian Federation, leading to the suspension of production of this sought-after medicinal product», — said Dmitry Matrosov, Deputy General Director for Development at DALKHIMPHARM.
Diamidazepam differs from other benzodiazepine and non-benzodiazepine tranquilizers by providing an activating effect with low levels of hypnotic and muscle relaxant effects.